MLKL and neoplasm: A higher phosphorylation level of MLKL has been correlated with a poorer prognosis and shorter survival in human patients with colon and esophageal cancer and the use of the MLKL inhibitor, NSA, was shown to significantly delay the tumor growth, highlighting the role of necroptosis in tumor promotion [131].